

Bedromed drops

Oromucosal drops



Bedromed drops is a pharmaceutical grade cannabinoid formulation derived from Bedrocan's standardised *Cannabis sativa* L. chemovars. It is formulated for oromucosal administration in a medium chain triglyceride (MCT) solution. MCT serves as a stable, well-tolerated lipophilic carrier suited to cannabinoid solubility, supporting consistent dosing and individualised titration.

Product information

- Derived from full-spectrum extract of the well-established **Bedrocan® chemovar** 'Afina'
- Preserved **natural cannabinoid and terpene profile** through a specialised manufacturing process
- Guaranteed pharmaceutical-grade quality through **EU-GMP certified manufacturing**



| Active Substance | Formulation | Starting Material* | Carrier Oil | Shelf Life | Packaging Size |
|------------------|------------------------------|--------------------|-------------|------------|----------------|
| ● THC | 25 mg/mL | Bedrocan® | MCT | 24 months | 30 mL |
| ● THC ● CBD | 10 mg/mL 10 mg/mL | Bedrocan® | MCT | 24 months | 30 mL |
| ● THC ● CBD | 25 mg/mL 25 mg/mL | Bedrocan® | MCT | 24 months | 30 mL |

● THC dominant ● Balanced

*) **Bedrocan**, *Cannabis sativa* L. 'Afina'



Medicine status

Bedromed drops is available on prescription only, subject to national cannabis and controlled substance regulations.

Intended use: Direct use or pharmacy compounding, based on regulatory classification in the respective market.



About Bedrocan

Bedrocan is recognised as a pioneer in the production of pharmaceutical-grade medicinal cannabis. Since 2003, Bedrocan has supplied cannabis flower products manufactured to pharmaceutical standards, ensuring quality, safety, and reproducibility for inhalation therapies. To address evolving clinical needs, Bedrocan has expanded its portfolio to include EU-GMP-certified oromucosal dosage forms such as Bedromed drops.

Clinical use

Intended use (emerging clinical evidence): Bedromed drops is supplied under special access provisions as an unapproved oromucosal formulation. Current research on the pharmacological class of THC-containing medicine has explored potential effects on pain perception and spasticity across several clinical conditions. Further clinical trials are required to determine the safety and efficacy of Bedromed drops. **Warnings and precautions:** Absolute and relative contraindications apply. Potential for medicine interactions must be considered.

Dosing & titration

Oromucosal drops, administered by syringe delivering 0.1 mL to 1.0 mL of solution.

Individualised dose titration

Principle: Start low, go slow. Maximum: 0.6 mL per day (equivalent to 15.0 mg THC).

Titration schedule (days 1–12)

A titration period is required to reach the optimal single dose and total daily dosage. The number and timing of doses should be tailored to the indication and adjusted according to individual response and tolerability.

- Stepwise escalation every 2 days, balancing morning and evening doses
- Starting dose is 0.1 mL at day 1-2 (equivalent to 2.5 mg THC daily)
- Maximum recommended daily dose is 0.6 mL at day 11–12 (equivalent to 15 mg THC daily)
- A stepwise escalation schedule over 12 days is suggested

More info?
See **Treatment Planning**

Ordering

Ordering process for pharmacies

You can find ordering details at www.bedrocan.com/order.

The Certificate of Analysis (latest batch) is available from your distributor or pharmacy.

Disclaimer This document is provided to support the clinical decision-making of prescribers and pharmacists. The product has not been granted marketing authorisation; therefore, its safety and efficacy have not undergone formal regulatory evaluation. While every effort has been made to ensure the accuracy of the scientific information available at the time of publication, Bedrocan International makes no representations or warranties regarding clinical outcomes. Prescribers should review all available evidence and use this product in accordance with applicable national regulations, professional standards, and the individual patient's clinical circumstances.

Copyright © 2026 Bedrocan International All rights reserved. No part of this document may be reproduced, distributed or transmitted in any form or by any means, including photocopying, without the prior written consent of Bedrocan International. Date of preparation: May 2026

Contact Bedrocan
info@bedrocan.com
bedrocan.com